Baxdrostat Adds an Option for Uncontrolled Hypertension

A new way to target aldosterone

The FDA’s May 15, 2026, decision adds baxdrostat to the options for adults whose blood pressure remains inadequately controlled with combination therapy. The practical significance is its mechanism: baxdrostat inhibits aldosterone synthase, the enzyme responsible for the final step in aldosterone production, rather than blocking the mineralocorticoid receptor after aldosterone has been released.

That distinction may matter when excess or inappropriately persistent aldosterone contributes to sodium retention, volume expansion and elevated blood pressure. It does not, however, make baxdrostat a universal next step for every above-target reading. The approved prescribing information should determine the eligible population, contraindications, dosing, monitoring and use with other drugs.

Potential candidates in practice are adults who remain above an individualized blood pressure goal despite multiple tolerated agents with complementary mechanisms. This may overlap substantially with resistant hypertension, conventionally defined as blood pressure above goal despite three antihypertensive classes at maximally tolerated doses—usually including a long-acting calcium channel blocker, a renin-angiotensin system blocker and a diuretic—or blood pressure controlled with at least four drugs.

Uncontrolled and resistant hypertension are not interchangeable. Before adding another medicine, clinicians generally assess measurement technique, home or ambulatory readings, adherence, interfering substances, dietary sodium, appropriate diuretic use and secondary causes. White-coat effect, missed doses or an undertreated regimen can produce apparent resistance without establishing a need for an additional mechanism.

What the clinical evidence showed

A key published study was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial in adults with treatment-resistant hypertension who were receiving stable treatment with at least three antihypertensive drugs, including a diuretic. Participants received once-daily baxdrostat at 0.5 mg, 1 mg or 2 mg, or placebo, for 12 weeks; 248 participants completed the trial.

The primary endpoint was change from baseline in seated systolic blood pressure. Reductions were dose-related. Compared with placebo, the 2-mg trial dose lowered systolic pressure by an additional 11.0 mm Hg, with a 95% confidence interval of 5.5 to 16.4 mm Hg in favor of baxdrostat. The placebo-adjusted difference with 1 mg was 8.1 mm Hg, with a 95% confidence interval of 2.8 to 13.5 mm Hg.

The 0.5-mg difference was not statistically significant.

These doses and results describe the phase 2 protocol, not necessarily the final FDA-approved regimen. The current product label remains the authoritative source for clinical use.

The phase 2 trial also supported the intended biological effect. Baxdrostat reduced aldosterone without meaningfully reducing cortisol, consistent with selective inhibition of aldosterone synthase over the closely related enzyme involved in cortisol synthesis. No adrenocortical insufficiency was reported. Two participants developed potassium levels of at least 6.0 mmol/L; the elevations did not recur after treatment interruption and restart, according to the published report.

How baxdrostat may fit into multidrug treatment

The new approval does not displace the foundational work of constructing and verifying an effective regimen. For many adults with apparent resistant hypertension, that means confirming adequate diuretic therapy, addressing sodium intake and reviewing whether the existing drugs cover complementary physiological pathways.

Mineralocorticoid receptor antagonists, particularly spironolactone, already have strong evidence as fourth-line therapy. In the randomized PATHWAY-2 crossover trial, spironolactone reduced home systolic blood pressure more than placebo, bisoprolol or doxazosin among adults with resistant hypertension. That evidence helped establish aldosterone-mediated sodium retention as an important therapeutic target.

Baxdrostat approaches the same hormonal pathway upstream. Mineralocorticoid receptor antagonists block aldosterone signaling at the receptor, while baxdrostat reduces aldosterone production. This provides a mechanistically distinct option, but the FDA approval alone does not establish that baxdrostat is superior to spironolactone, eplerenone or another established add-on drug for cardiovascular outcomes, tolerability, cost or treatment persistence.

Selection will therefore require more than counting medications. Relevant considerations include the composition and tolerability of the existing regimen, kidney function, baseline potassium, prior response to mineralocorticoid receptor blockade, suspected secondary hypertension and the approved label’s interaction and monitoring provisions. Direct comparative trials would be needed to determine whether one aldosterone-targeting strategy should routinely precede another.

Safety, monitoring and remaining uncertainties

Because aldosterone helps regulate sodium, potassium and intravascular volume, inhibition can create clinically important electrolyte or hemodynamic effects. The phase 2 potassium findings were uncommon and reversible, but the trial was too small and short to characterize uncommon harms or safety in every subgroup. Label-directed monitoring is especially important when baxdrostat is combined with other medicines that can raise potassium or alter kidney function.

The published phase 2 trial also cannot answer whether blood pressure lowering translates into fewer myocardial infarctions, strokes, heart failure events, kidney outcomes or deaths. Blood pressure is a clinically meaningful and accepted treatment target, but event reduction with this specific drug requires longer follow-up or dedicated outcomes evidence.

Generalizability is another limitation. Trial participants met defined resistant-hypertension criteria and were followed under protocol conditions, which may differ from routine care involving inconsistent adherence, frailty, advanced kidney disease or multiple interacting medications. The trial was industry funded, and several authors reported relationships with the sponsor. Those factors do not invalidate the findings, but they reinforce the value of regulatory review, independent replication and postmarketing surveillance.

The FDA’s annual novel-drug approval page documents the regulatory decision, but it is not a substitute for the full prescribing information and multidisciplinary review documents. Clinicians and formulary committees will need those materials to assess the precise indication, approved dose, subgroup evidence, contraindications, interactions and required monitoring.

Questions clinicians ask

Which patients are most likely to be considered for baxdrostat?

The approval applies to adults with hypertension inadequately controlled on combination therapy. Likely candidates overlap with true resistant hypertension, but clinicians should first confirm accurate measurements, adherence and an optimized multidrug regimen, while evaluating interfering substances and secondary causes that may explain persistent elevation.

Does baxdrostat replace spironolactone as fourth-line therapy?

Current evidence does not support a blanket replacement. Spironolactone has direct comparative evidence in resistant hypertension, whereas baxdrostat offers a different way to suppress the aldosterone pathway. Treatment order will depend on the FDA label, contraindications, tolerability, kidney function, potassium and future head-to-head evidence.

What laboratory issues are most relevant?

Potassium and kidney function are central because reducing aldosterone can impair potassium excretion and alter volume balance. The phase 2 trial reported two potassium measurements of at least 6.0 mmol/L. The approved prescribing information should guide baseline assessment, follow-up testing and management alongside other potassium-raising therapies.

Is cardiovascular risk reduction established?

No dedicated cardiovascular-outcomes benefit can be inferred from the 12-week phase 2 trial. Baxdrostat produced clinically relevant blood pressure reductions, but longer studies are needed to determine its effects on stroke, myocardial infarction, heart failure, kidney outcomes and mortality beyond the expected benefit of better blood pressure control.

References

1. Novel Drug Approvals for 2026 — US Food and Drug Administration, 2026
2. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension — The New England Journal of Medicine, 2023
3. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association — Hypertension, 2018
4. Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2) — The Lancet, 2015